Intarcia Therapeutics and pharmaceuticals maker Numab said today that they’ve logged several milestones in their joint project to develop a drug-device combination for treating inflammatory and autoimmune diseases.
Wädenswil, Switzerland-based Numab identified a pair of antibody-based compounds for the program, which aims to use the delivery and formulation technology developed by Cambridge, Mass.-based Intarcia.
The companies said Intarcia has successfully formulated versions of both the molecule targets identified by Numab.
“Achievement of this milestone for Intarcia further confirms the power of Numab’s discovery platform to produce next-generation antibody-based therapeutics, as well as our commitment to exceed expectations with our strategic partners,” Numab co-CEO David Urech said in prepared remarks.
“Our Numab collaboration continues to progress with cutting-edge science and technologies capable of delivering important new medicines and combinations in our therapeutic areas of focus. The progress brings us 1 step closer to delivering very promising and important new once or twice-yearly medicines in large and serious chronic diseases where we are uniquely positioned to address unmet needs,” added Intarcia chairman, president & CEO Kurt Graves.
